17.12.2021 aap Implantate AG  DE000A3H2101

DGAP-News: aap: Supervisory Board extends Management Board contracts until end of 2023


 

DGAP-News: aap Implantate AG / Key word(s): Personnel
aap: Supervisory Board extends Management Board contracts until end of 2023

17.12.2021 / 14:51
The issuer is solely responsible for the content of this announcement.


aap Implantate AG ("aap" or the "Company") announces that the Supervisory Board resolved to extend the contracts of Chairman of the Management Board (CEO) Rubino Di Girolamo and the two Management Board members Marek Hahn (CFO) and Agnieszka Mierzejewska (COO) by two years until the end of the financial year 2023.
 

"Over the past 2.5 years, under the leadership of Mr. Di Girolamo, the Management Board has managed to get aap back on track through extensive restructuring and refinancing despite severely hampered conditions caused by the COVID-19 pandemic," says Dr. med. Nathalie Krebs, Chairwoman of aap's Supervisory Board. "The next step is now to continue consistently on the way chosen and to achieve the operational and strategic goals that have been set. We are firmly convinced that with the Management Board in this constellation we are excellently positioned to lead aap on a profitable growth path after the successful transformation and repositioning and thereby create sustainable value for our shareholders."
 

Rubino Di Girolamo (59) has been aap's Chairman of the Management Board (CEO) since May 2019. He is responsible for Corporate Development, Research & Development Future Technologies, Corporate Risk and Compliance Management.
 

Marek Hahn (46) has held the position of member of the Management Board (CFO) at aap since April 2010. In his function as CFO he is responsible for Finance/Controlling, Human Resources, IT, Legal Affairs, Investor and Public Relations as well as Administration.
 

Agnieszka Mierzejewska (39) has been a member of the Management Board (COO) at aap since January 2021. She is responsible for Sales & Marketing, Production, Research & Development Trauma, Quality Assurance and Regulatory Affairs.

 

----------------------------------------------------------------
aap
Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For queries, please contact:
aap Implantate AG; Fabian Franke; Head of Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49 (0)30 75019 - 134; Fax: +49 (0)30 75019 - 290; Email: [email protected]



17.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: [email protected]
Internet: www.aap.de
ISIN: DE000A3H2101
WKN: A3H210
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1259572

 
End of News DGAP News Service

1259572  17.12.2021 

fncls.ssp?fn=show_t_gif&application_id=1259572&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 10,49 10,90 10,78 11,74 9,33 12,17 12,20
EBITDA1,2 -7,89 -6,21 -6,41 -5,14 -4,77 -0,77 -1,70
EBITDA-Marge3 -75,21 -56,97 -59,46 -43,78 -51,13 -6,33 -13,93
EBIT1,4 -10,18 -7,99 -8,13 -19,77 -7,89 -2,61 -2,50
EBIT-Marge5 -97,04 -73,30 -75,42 -168,40 -84,57 -21,45 -20,49
Jahresüberschuss1 -9,33 -8,94 -7,67 -19,52 -8,79 -2,52 -2,80
Netto-Marge6 -88,94 -82,02 -71,15 -166,27 -94,21 -20,71 -22,95
Cashflow1,7 -7,20 -5,43 -5,92 -5,77 -3,68 -2,47 0,00
Ergebnis je Aktie8 4,70 -3,10 -2,70 -6,10 -2,79 -0,51 -0,47
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
aap Implantate
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A3H210 2,380 14,18
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 2,60 0,00 -1,81
KBV KCV KUV EV/EBITDA
1,17 - 1,17 -20,76
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,00 0,00 0,00 01.06.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 12.08.2022 - 31.03.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-17,33% -23,89% -20,67% -15,60%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu aap Implantate AG  ISIN: DE000A3H2101 können Sie bei DGAP abrufen


Medtech , A3H210 , AAQ1 , XETR:AAQ1